Clinical Trial of Qizhu Yuling Prescription in the Prevention and Treatment of Esophagus Cancer

Inclusion Criteria:

* 1\. Esophageal cancer without esophagogastric junction pT1-4aN + M0 (stage IIB-IVA) meeting the diagnostic criteria without recurrence or metastasis;

  2\. Patients who have completed adjuvant therapy (including adjuvant radiotherapy, adjuvant chemotherapy, adjuvant chemotherapy + radiotherapy) within 6 months after R0 resection for esophageal cancer;

  3\. ECOG score 0-2;

  4\. 18-75 years old;

  5\. Expected survival ≥ 3 months;

  6\. Subjects voluntarily signed informed consent.

Exclusion Criteria:

* 1\. Combined with primary tumor at other sites;

  2\. Patients complicated with severe primary diseases of heart, cerebral vessels, liver, kidney and hematopoietic system;

  3\. Patients with mental illness and mental and language disorders;

  4\. Participation in other clinical trials within 3 months;

  5\. Patients with known hypersensitivity or intolerance to study drug.